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Tumour suppressor candidate 7 (TUSC7) is a novel tumor suppressor gene generating
long non-coding RNA (lncRNAs) in several types of human cancers. The expression and
function of TUSC7 in human brain glioma has yet to be elucidated. In this study, TUSC7
was poorly expressed in tissues and cell lines of glioma, and the lower expression was
correlated with glioma of the worse histological grade. Moreover, TUSC7 is a prognostic
biomarker of glioma patients. Up-regulation of TUSC7 suppressed cellular proliferation
and invasion of glioma cells, and accelerated cellular apoptosis. Bioinformatics analysis
showed that TUSC7 specifically binds to miR-23b. MiR-23b was up-regulated in glioma
and negatively correlated with the expression of TUSC7. The miR-23b expression
was inhibited remarkably by the upregulation of TUSC7 and the reciprocal inhibition
was determined between TUSC7 and miR-23b.RNA pull-down and luciferase reporter
assays were used to validate the sequence-specific correlation between miR-23b and
TUSC7. TUSC7 inhibited the proliferation, migration and invasion of glioma cells and
promoted cellular apoptosis largely bypassing miR-23b. We conclude that the lncRNA
TUSC7 acted as a tumor suppressor gene negatively regulated by miR-23b, suggesting
a novel therapeutic strategy against gliomas.
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INTRODUCTION
Human brain glioma is the most general intracranial tumor, which is characterized by malignant
proliferation, chemotherapy resistance, intracranial metastasis, and high-frequency recurrence
(Kuhnt et al., 2011; Hu et al., 2016). The mortality due to glioma is the highest among the nervous
system tumors, and the prognosis is poor (Zeng et al., 2015; Chen et al., 2016). Until now, surgery
was indicated as the first-line treatment for gliomas. Chemotherapy and radiotherapy after initial
surgical resection are considered effective in preventing recurrence and metastasis (Mrugala, 2013;
Alifieris and Trafalis, 2015). However, chemotherapy and radiotherapy does not work for everyone
with glioma, they help about half the people treated (Spinelli et al., 2012; Alexander et al., 2013).
Therefore, the prognosis of patients, especially with high-grade glioma is still poor, despite prompt,
and comprehensive treatment. The median survival time of patients with anaplastic astrocytoma
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is approximately 2–3 years. Among patients with aggressive
glioblastomas, the median survival time is nearly 12 to
14.6 months, and the 2-year median survival rate is 30% (Nieder
et al., 2008). Therefore, discovery of new therapeutic strategies
and targets against human brain glioma is imperative.
Long non-coding RNA (lncRNA) is a type of endogenous
RNA, which is not translated to protein. Over the past several
years, studies involving lncRNAs increased rapidly. LncRNAs
mediate critical biological events such as cell cycle, autophagy,
and apoptosis (Song et al., 2014; Xu et al., 2014; Zhao et al.,
2014). A few lncRNAs show anomalous expression and function
in malignant tumors, by acting as oncogenes or tumor suppressor
genes (Modali et al., 2015; Wang X. et al., 2015).
Tumor suppressor candidate 7 (TUSC7) located at 3q13.31
encodes a lncRNA, which is a potential tumor suppressor in
gastric cancer, non-small-cell lung cancer, osteosarcoma and
hepatocellular carcinoma (Qi et al., 2015; Cong et al., 2016;
Wang Y. et al., 2016; Wang Z. et al., 2016). However, nothing is
known about the expression level of TUSC7 in glioma or whether
it is involved in the gliomagenesis. In our microarray assays,
TUSC7 showed greater than 10-fold down-regulation in human
brain glioma tissue than in control samples. Detection of low
levels of TUSC7 expression in glioma tissues suggested a tumor
suppressor role.
In this study, the expression of lncRNA TUSC7 was detected,
and its regulatory effects and mechanisms in glioma cells were
examined. Our findings facilitated the development of effective
clinical interventions targeting human brain gliomas.
MATERIALS AND METHODS
Ethical Approval
All the patients were informed about the purposes of the study
and consequently have signed their “consent of the patient.”
All investigations conformed to the principles outlined in the
Declaration of Helsinki and were performed with permission by
the responsible Medical Ethics Committees of China Medical
University (CMU-2010018).
Clinical Specimens
A total of 39 glioma and 17 adjacent normal brain tissues
(NBT) were obtained from Shengjing Hospital and Affiliated
First Hospital of China Medical University from December
2010 to November 2011. The patients were not exposed to
radiation or chemotherapy before surgery. The tissue samples
were stored in liquid nitrogen immediately after surgery. All the
pathological data were assembled according to the 2007 WHO
classification. The patients’ age (mean± SD) was 54.1± 6.8 years
(ranging from 45 to 62 years) including 24 males and 15
females. All glioma patients included nine cases of grade I,
10 cases of grade II, 11 cases of grade III, and nine cases
of grade IV, according to pathological diagnosis. This study
was approved by the Medical Ethics Committees of China
Medical University and the patients provided written informed
consent.
Cell Culture
Human brain glioma U251 and U87 cell lines and HEK
293T cells were obtained from China Academy of Chinese
Medical Sciences. The cells were cultured in DMEM medium
supplemented with 10% fetal bovine serum (Life Technologies
Corporation, Carlsbad, CA, USA), and cultured at 37◦C with 5%
CO2. Primary normal human astrocytes (NHA) were obtained
from the Sciencell Research Laboratories (Carlsbad, CA, USA)
and cultured in special Astrocyte Basal Medium (Clonetics–
BioWhittaker) supplemented with 10 µg/mL human epidermal
growth factor, 10 mg/mL insulin, 25 µg/mL progesterone,
50 mg/mL transferrin, 50 mg/mL gentamicin, 50 µg/mL
amphotericin, and 10% FBS.
Quantitative Real Time-PCR (qRT-PCR)
Total RNA was harvested with TRIzol reagent (Life Technologies
Corporation, Carlsbad, CA, USA) and reverse transcribed to
cDNA using Reverse-Transcription Kit (Applied Biosystems,
USA). The expression of TUSC7 and miR-23b was detected
with SYBR (Applied Biosystems, Foster City, CA, USA). The
TUSC7 primers were: 5′-TTTATGCTTGAGCCTTGA-3′ (sense)
and 5′-CTTGCCTGAAATACTTGC-3′ (antisense). GAPDH and
U6 served as endogenic control genes. The primers of miR-
23b, GAPDH and U6 were obtained from Genescript Company
(Nanjing, China). The Ct value of the detected gene varied
between 18 and 30, and was quantified using the 2−11Ct method
(Song et al., 2014).
Transfection
The over-expression vector pE-TUSC7 and empty pEGFP-N1
(NC) was obtained from Genescript Company (Nanjing, China).
Cells at approximately 60–70% confluence were transfected with
LipofectamineTM 3000 Reagent (Life Technologies Corporation,
Carlsbad, CA, USA) according to protocols after 24 h of culture.
G418 (Invitrogen, Carlsbad, CA, USA) was used to establish
stable cell lines, and qRT-PCR was used to determine the
transfection efficiencies. Moreover, miR-23b agonist (agomir-
23b), miR-23b antagonist (antagomir-23b), and their NC
(agomir-NC and antagomir-NC) (Sangon, Shanghai, China) were
transfected into U251 and U87 cells, respectively, or cells with
TUSC7 over-expression transiently.
Cell Proliferation
U251 and U87 cells (2 × 104/well) were seeded in a 96-
well plate at a density of 2000 cells/well. Following addition
of 20 µL of 0.5 mg/mL MTT solution (Sigma, USA) to
each well, the plate was incubated at 37◦C. After 4 h, the
MTT solution was discarded, and 0.2 mL DMSO was added
to each well. Before the 96-well plate was analyzed on the
SpectraMax M5 microplate reader (Molecular Devices, USA)
at 450 nm, it was incubated for 30 min. The cell viability
was calculated as follows: (OD value of test group – OD
value of blank group)/(OD value of control group – OD
value of blank group). Five replicate wells were set up in
each group and five independent experiments were conducted
repeatedly.
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Apoptosis
Apoptosis was assessed using dual-color flow cytometry. Cells
were harvested, and apoptosis was detected with Annexin
V-FITC apoptosis detection kit (KeyGEN, China) following
the manufacturer’s protocol. Flow cytometry (BD, USA) and
CELLQuest 3.0 software (BD, USA) were used to analyze the data.
Cell Migration and Invasion Assay
Migration and invasion of U251 and U87 cells in vitro were
assayed using Transwell chamber (Costar, Corning, NY, USA)
with polycarbonic membrane (6.5 mm in diameter, 8 µm
pore size). In the migration assay, the transfected cells were
resuspended in 100 µL serum-free medium at a density of
5 × 105 cells/mL and added in the upper chamber. Six hundred
microliters of DMEM/high-glucose or DMEM/F12 medium
supplemented with 10% FBS was added to the lower chamber.
After incubation for 48 h, the cells on the upper membrane
surface were mechanically removed. Cells that had migrated or
invaded to the lower side of the membrane were fixed with
methanol and stained with 20% Giemsa. Stained cells were
counted under a microscope in five randomly chosen fields and
the average number was calculated. In the invasion assay, the
Transwell membrane was coated with 80 µL of Matrigel solution
(500 ng/µL; BD, Franklin Lakes, NJ, USA) and incubated at 37◦C
for 4 h, the remaining steps were similar to the migration assay.
Luciferase Reporter Assay
Dual-luciferase reporter plasmids including pmiR-TUSC7-wt
(containing miR-23b target binding sequence in TUSC7) and
pmiR-MACC1-mut (containing the mutant binding sequence)
were constructed by Genescript (Nanjing, China). Luciferase
assay was conducted by co-transfecting pmiR-TUSC7-wt or
pmiR-MACC1-mut and agomir-23b or agomir-NC into HEK
293T cells. A dual-luciferase reporter assay system (Promega,
USA) was used to detect the luciferase activity after co-
transfection in HEK 293T cells for 48 h according to the
manufacturer’s protocol.
RNA Pull-Down Assay
Probes for miR-23b or TUSC7 were biotinylated (Sangon,
Shanghai, China) and transfected into glioma cells. Then 48 h
later, cells were harvested and lysed. The samples were incubated
with Dynabeads M-280 Streptavidin (Invitrogen, Carlsbad, CA,
USA). Biotinylated miR-23b was incubated with beads for 10 min,
and treated with washing buffer. The bound RNAs were analyzed
by qRT-PCR.
RNA Immunoprecipitation (RIP)
RNA Immunoprecipitation experiments were performed using
the Magna RIP RNA-Binding Protein IP Kit (Millipore, Bedford,
MA, USA) and the Ago2 antibody (2897; Cell Signaling, Danvers,
MA, USA) according to the manufacturer’s instructions and
previous studies (Zhao et al., 2014). Eventually, purified RNAs
in the precipitates were used to determine TUSC7 and miR-23b
expression.
Statistical Analysis
Statistical analysis was accomplished with SPSS 13.0 (IBM,
Chicago, IL, USA). The data were presented as mean ± SD of
three independent experiments and compared using Student’s
t-test and one-way ANOVA. The association between TUSC7
expression and pathological grade was determined in univariate
analysis and binary logistic regression. Overall survival rate was
calculated by Kaplan–Meier method with the log-rank test for
comparisons. P < 0.05 indicated significant difference.
RESULTS
TUSC7 Down-Regulated in Glioma
Specimens and Cell Lines
In our microarray assays, the expression of TUSC7 showed over
10-fold down-regulation in human brain glioma tissue than in
control samples (Figure 1). TUSC7 expression in glioma samples
was significantly lower than in the NBT samples (Figure 2A).
The expression of TUSC7 in U251 and U87 cells was also down-
regulated compared with the NHA cells (p < 0.05) (Figure 2B),
which provided initial evidence suggesting that the depletion of
TUSC7 plays a key role in glioma formation.
The correlation between TUSC7 expression and specific
clinical characteristics of glioma indicated that glioma with
a worse histological grade showed a tendency to express
significantly lower TUSC7 (p < 0.05). However, miR-23b
expression was not significantly correlated with other clinical
characteristics, such as age, gender and metastasis (p> 0.05).
TUSC7 Acts as a Prognostic Biomarker
in Glioma Patients
Interestingly, TUSC7 was found to be a prognostic biomarker
in glioma patients. Compared with glioma patients with higher
TUSC7 expression, a lower expression of TUSC7 was associated
with a remarkably shorter survival time in Kaplan–Meier analysis
(Figure 2C), and a significantly worse prognosis in the univariate
Cox proportional hazards regression analysis of overall survival
(HR = 2.813, 95% CI: 1.504–6.172; P = 0.017). The results
established that down-regulation of TUSC7 plays an important
role in the tumorigenesis of glioma.
FIGURE 1 | LncRNA microarray analysis of total RNA isolated from five
glioma tissues and corresponding adjacent normal brain tissues. 1–5:
glioma, 1p–5p: normal.
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FIGURE 2 | (A) Compared with normal brain tissues (NBT) and normal human astrocytes (NHA) cells, TUSC7 was poorly expressed in human glioma tissues and
cell lines. (B) Glioma tissues with worse histological grade exhibited decreased TUSC7 expression. (C) Kaplan–Meier analysis indicated that lower TUSC7
expression was associated with a significantly shorter survival time than higher TUSC7 expression. Data are presented as mean ± SD (n = 5, each group).
∗P < 0.05 vs. NBT or NHA group.
FIGURE 3 | (A) TUSC7 expression was up-regulated significant by transfection of pE-TUSC7 in U251 and U87 cell lines. (B,C) TUSC7 over-expression inhibited cell
viability and advanced apoptosis of U251 and U87 cells. (D) TUSC7 over-expression impeded the migration and invasion of U251 and U87 cells, Scale bars
represent 100 µm.∗P < 0.05 vs. Blank and NC group.
Up-Regulation of TUSC7 Inhibits the
Malignant Behavior of Glioma Cells
To investigate whether TUSC7 affected the malignant behavior
of U251 and U87 cells, cells stably over-expressing TUSC7
were constructed (Figure 3A). As shown in Figures 3B,C,
TUSC7 over-expression significantly inhibited cell viability and
promoted the apoptosis of both U251 and U87 cells when
compared with the NC groups (P < 0.05). Over-expression of
TUSC7 impeded the migration by roughly 42% in U251 cells and
by nearly 45% in U87 cells (Figure 3D). A corresponding effect
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on invasion was also observed in a parallel invasion assay, which
showed a significant inhibition of invasion in U251 and U87 cells
compared with the respective NC group (P < 0.05).
Reciprocal Inhibition between miR-23b
and TUSC7 in Glioma
Bioinformatics analysis was used to search for the potential
targeted microRNAs of TUSC7, such as Targetscan, Starbase, and
microRNA.org. Together, a miR-23b binding site (1125–1140 bp)
was found in TUSC7 transcript, and TUSC7 was a predicted
gene of miR-23b (Figure 4A). Moreover, Qi et al. (2015) reported
a reciprocal regulation between miR-23b and TUSC7 in gastric
cancer (Xu et al., 2014). However, such a regulatory relationship
in glioma is still unclear.
As shown in Figure 4B, miR-23b was up-regulated
significantly in glioma tissues than that in the normal
tissues, showing a negative correlation with TUSC7 in the
Pearson’s correlation analysis. To establish whether TUSC7
was a target gene of miR-23b, agomir-23b, and antagomir-23b
were transfected into U251 and U87 cells. Further, qRT-PCR
showed that agomir-23b down-regulated TUSC7 expression
and antagomir-23b exhibited the opposite effect in U251 and
U87 cells (P < 0.01; Figure 4C). Moreover, the dual-luciferase
reporter assay indicated that the relative luciferase activity was
decreased in HEK 293T transfected with wild type vector via
enhanced miR-23b expression, and the foregoing inhibition was
recovered by Mut vector. These results suggested that TUSC7
was a specific target gene of miR-23b (Figure 4D).
Furthermore, the biotin–avidin pull-down assay showed that
TUSC7 was pulled down by biotinylated miR-23b (Figure 4E),
but not by biotinylated miR-23b-mut containing mutations in the
putative binding site involvingTUSC7 and miR-23b. The findings
suggested that miR-23b was sequenced specifically and directly
bound to TUSC7. Conversely, the biotin-labeled TUSC7 probe
was used to demonstrate that TUSC7 was also pulled down by
miR-23b (Figure 4F).
FIGURE 4 | (A) Putative binding sites of miR-23b within TUSC7 mRNA, and the sequences of wild-type and mutant-type vectors. (B) MiR-23b was highly expressed
in human glioma tissues and cell lines. (C) Compared with control groups, agomir-23b increased the expression of miR-23b in U251 and U87 cells, antagomir-23b
inhibited miR-23b expression. (D) The relative luciferase activities were inhibited in the HEK-293 cells co-transfected with wild-type vector and p agomir-23b, and not
with the mutant-type vector. Firefly luciferase activity was normalized to Renilla luciferase. (E) Detection of TUSC7 mRNA using qRT-PCR in the sample pulled down
by biotinylated miR-23b. (F) Detection of miR-23b mRNA using qRT-PCR in the sample pulled down by biotinylated TUSC7. (G) MiR-23b expression was
down-regulated significantly by TUSC7 over-expression in U251 and U87 cell lines. (H,I) Association of TUSC7 and miR-23b with Ago2 in U251 and U87 cells.
Cellular lysates from U251 and U87 cells were used for RIP with antibody against Ago2. TUSC7 and miR-23b expression levels were detected using qRT-PCR.
∗P < 0.05.
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Interestingly, the stable over-expression of TUSC7
significantly inhibited the expression of miR-23b in U251
and U87 cells (P < 0.05) (Figure 4G). All these results suggested
a reciprocal inhibition between miR-23b and TUSC7 in glioma.
The RNA-induced silencing complex (RISC) is a major
mechanism of miRNAs to silence target genes, and Ago2 protein
is a key constituent of RISC complex. To validate the presence of
both miR-23b and TUSC7 in the RISC complex, a RIP experiment
was conducted using Ago2 antibody to confirm that both miR-
23b and TUSC7 were found in the Ago2 pellet (Figures 4H,I).
Down-Regulation of miR-23b Inhibits the
Malignant Behavior of Glioma Cells
The antagomiR-23b-inhibited U251 and U87 cells were used
to investigate the malignant behavior of miR-23b. As shown
in Figures 5A–C, the viability of cells with miR-23b down-
regulation decreased significantly, and the apoptotic rate was
enhanced remarkably, while the migration and invasion were
reduced significantly in both U251 and U87 cells compared with
the respective NC groups (P < 0.05).
Up-Regulation of miR-23b Mostly
Reversed TUSC7-Induced Regulation of
Glioma Cells
Due to the reciprocal inhibition between TUSC7 and miR-23b,
the regulatory role of miR-23b remains unclear. Agomir-23b was
used to transfect into U251 and U87 cells stably over-expressing
TUSC7.
As shown in Figures 6A,B, up-regulated miR-23b largely
reversed the inhibitory effect of TUSC7 on cell proliferation,
migration, and invasion. Moreover, over-expression of miR-
23b also substantially suppressed cellular apoptosis promoted
by TUSC7 (Figure 6C). The regulatory effects of TUSC7 on
biological behaviors of glioma cells were reversed largely by miR-
23b. The results indicated that miR-23b regulated the biological
behavior of glioma cells via TUSC-7.
DISCUSSION
It is well known that human brain glioma cells are strongly
resistant to chemotherapy and radiotherapy, with a low apoptotic
ratio and high malignant proliferative ability (Dahlrot, 2014; Lim
et al., 2014). Those features are helpful to cells malignant growth
and invasion of glioma, which may be a key factor underlying
poor prognosis and recurrence of glioma (Wang F. et al., 2014).
Recent studies suggest that more than 75% of the human
genome can be transcribed to RNA. However, only about 1.2% of
those RNAs are translated to proteins. A large proportion of non-
coding RNAs might play important and complex physiological
and pathological roles (Alaimo et al., 2014). Recent reports
suggest that lncRNAs have a functional role in cell proliferation,
apoptosis, autophagy, invasion, and metastasis (Fang et al., 2014;
FIGURE 5 | (A,B) Mir-23b down-regulation inhibited cell viability and advanced apoptosis of U251 and U87 cells. (C) Mir-23b down-regulation disrupted the
migration and invasion of U251 and U87 cells, Scale bars represent 100 µm.∗P < 0.05 vs. Blank and NC group.
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FIGURE 6 | Over-expression of miR-23b partly reversed TUSC7-induced inhibition of proliferation (A), migration and invasion (B), and partly reversed
TUSC7-induced apoptosis (C) in U251 and U87 cells. Scale bars represent 100 µm. ∗P < 0.05, ∗∗P < 0.01.
Wang Y. et al., 2014; Nie et al., 2015). The functions of a
few lncRNAs and their relationship with disease have been
established, although many of these genes were screened and
identified recently. Intriguingly, increasing evidence suggests that
lncRNAs regulate tumorigenesis (Banet et al., 2000; Kraus et al.,
2015).
In order to identify the lncRNA expression profiles in human
brain glioma, we used microarray assays together with real-time
PCR to screen and identify several lncRNAs with significantly
altered expression. Among the lncRNAs, TUSC7 exhibited over
10-fold down-regulation in human brain glioma tissue than in
control samples. Subsequently, the down-regulated expression
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of TUSC7 was confirmed in glioma tissues and cells, and
patients with worse histological grade displayed significantly
lower TUSC7 expression.
We further explored the effect of TUSC7 on the biological
behavior of glioma cells U251 and U87. Our results showed
that over-expression of TUSC7 significantly repressed cell
proliferation, migration, and invasion, while promoted cellular
apoptosis in both U251 and U87. These results suggest that
TUSC7 might act as a tumor suppressor and play a crucial role
in the tumorigenesis of glioma.
Bioinformatics analysis is an effective tool to predict and
validate the target genes of specific microRNAs, including
lncRNAs. In this study, TUSC7 mRNA was a potential target
of miR-23b following computational analysis using Targetscan,
Starbase and microRNA.org. Gain and loss functions were used
to confirm TUSC7 as a direct and specific target of miR-
23b. First, miR-23b expression was up-regulated significantly
in glioma, and its effect on U251 and U87 was consistent
with Chen’s report (Chen et al., 2012). TUSC7 expression
was negatively correlated with the expression of miR-23b
in glioma. Second, the luciferase reporter assay and RNA
pull-down assay strongly validated the sequence-specific and
direct combination between miR-23b and TUSC7. Finally,
loss- and gain-of-function genetic approaches involving miR-
23b negatively regulated the expression of TUSC7 in U251
and U87 cells. Conversely, TUSC7 also significantly negatively
regulated miR-23b expression in glioma U251 and U87 cells.
Reversed pull-down assay confirmed the specific and direct
combination between miR-23b and TUSC7. These results
indicated a reciprocal inhibition between miR-23b and TUSC7
in glioma. We elucidated the underlying mechanism of the
miRNA/lncRNA trans-regulatory function via RIP with anti-
Ago2 antibody. The results support the role of RISC in the
reciprocal repression, which is consistent with our previous
studies. LncRNA CASC2 was another tumor suppressing gene
in glioma, which suppressed the malignant behavior of glioma
largely by inhibiting miR-21 in RISC complex (Wang P. et al.,
2015).
Based on the evidence suggesting that TUSC7 regulated
the biological behavior of glioma cells via reciprocal inhibition
between miR-23b and TUSC7, we hypothesized that TUSC7
acted by directly silencing miR-23b expression. In order to test
our hypothesis, agomir-23b was transfected into TUSC7-over-
expressing glioma cells and found that miR-23b enhancement
clearly promoted the malignant behavior of glioma cells. Further,
the regulatory effects of TUSC7 on cells were reversed by partially
up-regulating miR-23b, supporting our hypothesis significantly.
In summary, decreased expression of TUSC7 is a prognostic
biomarker associated with poor prognosis in glioma patients.
TUSC7 was targeted and inhibited reciprocally by miR-23b, and
acted as a tumor-suppressing gene, which inhibited the malignant
behavior of glioma cells. Our study facilitated the understandings
of TUSC7 function in gliomagenesis, and provided a novel
therapeutic target.
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